New hope for Hard-to-Treat breast cancer: drug combo aims to outsmart tumors
NCT ID NCT04265872
First seen Feb 16, 2026 · Last updated May 20, 2026 · Updated 18 times
Summary
This early-stage trial tests a new approach for women with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. The study uses bortezomib first to make cancer cells more vulnerable, then gives pembrolizumab and cisplatin to attack the tumor. About 20 participants will be closely monitored to see if the tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Contact
Conditions
Explore the condition pages connected to this study.